Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HCM HUTCHMED	$15.69 +1.8%	$14.80	$11.51 ▼ $21.50	$2.69B	0.52	101,032 shs	47,966 shs
MRTX Mirati Therapeutics	$58.70	$58.82	$27.30 ▼ $64.41	$4.12B	0.77	2.76 million shs	N/A
PTCT PTC Therapeutics	$49.15 +1.2%	$48.24	$29.02 ▼ $58.38	$3.85B	0.5	859,133 shs	1.06 million shs
SAGE Sage Therapeutics	$9.08	$7.47	$4.62 ▼ $13.47	$568.60M	0.29	1.29 million shs	1.48 million shs
ZLAB Zai Lab	$35.49 +0.9%	$33.66	$16.01 ▼ $44.34	$3.91B	0.99	906,548 shs	424,232 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HCM HUTCHMED	+1.82%	+1.36%	+15.37%	+2.89%	-8.89%
MRTX Mirati Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
PTCT PTC Therapeutics	+1.15%	+0.53%	+0.66%	+5.18%	+61.73%
SAGE Sage Therapeutics	0.00%	-1.84%	+37.16%	+23.20%	-16.08%
ZLAB Zai Lab	+0.91%	-3.98%	+13.79%	-3.27%	+104.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HCM HUTCHMED	1.7721 of 5 stars	2.0	4.0	0.0	1.8	0.0	1.9
MRTX Mirati Therapeutics	0.4723 of 5 stars	0.0	0.0	4.7	0.6	0.0	0.6
PTCT PTC Therapeutics	4.3316 of 5 stars	4.3	1.0	4.4	1.7	0.8	1.3
SAGE Sage Therapeutics	3.2191 of 5 stars	2.0	2.0	4.0	2.5	1.7	0.6
ZLAB Zai Lab	3.3948 of 5 stars	3.4	5.0	0.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HCM HUTCHMED	2.00	Hold	$19.00	21.10% Upside
MRTX Mirati Therapeutics	0.00	N/A	N/A	N/A
PTCT PTC Therapeutics	2.67	Moderate Buy	$65.00	32.25% Upside
SAGE Sage Therapeutics	2.00	Hold	$8.93	-1.62% Downside
ZLAB Zai Lab	2.80	Moderate Buy	$54.28	52.93% Upside

Current Analyst Ratings Breakdown

Latest MRTX, HCM, PTCT, ZLAB, and SAGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	ZLAB Zai Lab	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$73.00 ➝ $75.00
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	PTCT PTC Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/27/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$68.00 ➝ $74.00
5/13/2025	HCM HUTCHMED	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/9/2025	PTCT PTC Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$55.00 ➝ $68.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HCM HUTCHMED	$630.20M	4.34	$0.29 per share	53.65	$4.43 per share	3.54
MRTX Mirati Therapeutics	$12.44M	331.01	N/A	N/A	$17.31 per share	3.39
PTCT PTC Therapeutics	$806.78M	4.83	N/A	N/A	($14.24) per share	-3.45
SAGE Sage Therapeutics	$41.24M	13.79	N/A	N/A	$7.60 per share	1.19
ZLAB Zai Lab	$398.99M	9.88	N/A	N/A	$7.68 per share	4.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HCM HUTCHMED	$37.73M	N/A	0.00	10.75	N/A	N/A	N/A	N/A	N/A
MRTX Mirati Therapeutics	-$740.87M	-$12.22	N/A	N/A	N/A	-1,900.65%	-82.15%	-67.82%	N/A
PTCT PTC Therapeutics	-$363.30M	$6.51	7.55	N/A	N/A	33.56%	-78.56%	32.11%	8/6/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)
ZLAB Zai Lab	-$257.10M	-$2.49	N/A	N/A	N/A	-60.26%	-33.35%	-23.28%	8/5/2025 (Estimated)

Latest MRTX, HCM, PTCT, ZLAB, and SAGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	SAGE Sage Therapeutics	-$0.96	N/A	N/A	N/A	$16.69 million	N/A
5/8/2025	Q1 2025	ZLAB Zai Lab	-$0.50	-$0.45	+$0.05	-$0.45	$118.40 million	$106.49 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
MRTX Mirati Therapeutics	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HCM HUTCHMED	0.08	2.83	2.70
MRTX Mirati Therapeutics	N/A	7.54	7.40
PTCT PTC Therapeutics	N/A	3.89	3.85
SAGE Sage Therapeutics	N/A	9.13	9.13
ZLAB Zai Lab	N/A	3.26	3.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HCM HUTCHMED	8.82%
MRTX Mirati Therapeutics	N/A
PTCT PTC Therapeutics	N/A
SAGE Sage Therapeutics	99.22%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
HCM HUTCHMED	3.60%
MRTX Mirati Therapeutics	3.26%
PTCT PTC Therapeutics	5.50%
SAGE Sage Therapeutics	5.50%
ZLAB Zai Lab	4.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HCM HUTCHMED	1,811	174.32 million	168.05 million	Not Optionable
MRTX Mirati Therapeutics	587	70.15 million	67.86 million	Optionable
PTCT PTC Therapeutics	1,410	79.26 million	74.90 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable
ZLAB Zai Lab	1,950	111.08 million	105.57 million	Optionable

MRTX, HCM, PTCT, ZLAB, and SAGE Headlines

Recent News About These Companies

Cantor Fitzgerald Lowers Earnings Estimates for Zai Lab

2 hours ago | marketbeat.com

FY2026 EPS Estimates for Zai Lab Raised by Leerink Partnrs

July 3 at 2:59 AM | americanbankingnews.com

Leerink Partnrs Analysts Lift Earnings Estimates for Zai Lab

July 2 at 8:44 AM | marketbeat.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells 6,918 Shares of Stock

July 2 at 5:40 AM | insidertrades.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells $245,727.36 in Stock

July 1 at 6:05 PM | marketbeat.com

Amgen and Zai Lab’s trial of gastric cancer therapy meets primary endpoint

July 1 at 7:52 AM | finance.yahoo.com

Amgen, Zai Lab succeed in gastric cancer study

June 30 at 4:45 PM | msn.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Recommendation of "Moderate Buy" by Analysts

June 30 at 3:32 PM | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Price Target Raised to $75.00 at Leerink Partners

June 30 at 2:54 PM | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?

June 30 at 12:14 PM | marketbeat.com

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

June 30 at 9:05 AM | businesswire.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells $855,160.97 in Stock

June 30 at 4:09 AM | americanbankingnews.com

Oppenheimer Asset Management Inc. Makes New Investment in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

June 30 at 3:26 AM | marketbeat.com

Zai Lab (ZLAB) chief legal officer sells $212k in shares

June 29, 2025 | investing.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells $96,647.75 in Stock

June 28, 2025 | insidertrades.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Shares Purchased by Mirae Asset Global Investments Co. Ltd.

June 28, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Stock Rating Lowered by Wall Street Zen

June 28, 2025 | americanbankingnews.com

Zai Lab (NASDAQ:ZLAB) Downgraded to Hold Rating by Wall Street Zen

June 27, 2025 | marketbeat.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells 2,675 Shares of Stock

June 27, 2025 | marketbeat.com

Ying Du Sells 23,669 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock

June 27, 2025 | marketbeat.com

Zai Lab Limited (ZLAB) - Yahoo Finance

June 27, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRTX, HCM, PTCT, ZLAB, and SAGE Company Descriptions

HUTCHMED NASDAQ:HCM

$15.69 +0.28 (+1.82%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$16.00 +0.31 (+1.97%)

As of 08:00 AM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Mirati Therapeutics NASDAQ:MRTX

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

PTC Therapeutics NASDAQ:PTCT

$49.15 +0.56 (+1.15%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$49.40 +0.25 (+0.51%)

As of 08:50 AM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Sage Therapeutics NASDAQ:SAGE

$9.08 0.00 (0.00%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$9.09 +0.01 (+0.06%)

As of 08:48 AM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Zai Lab NASDAQ:ZLAB

$35.49 +0.32 (+0.91%)

Closing price 07/2/2025 04:00 PM Eastern

Extended Trading

$36.60 +1.11 (+3.11%)

As of 08:48 AM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time